RxDoctor Payments Data

Satoshi Kamada, MD

Internal Medicine · Irvine, CANPI 1073630521

Payments from drug & device makers

$5,461in general payments, 2019–2025

Across 251 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • AstraZeneca$1K
  • Pfizer$500
  • Novo Nordisk$437
  • Lilly USA, LLC$334
  • Merck$285
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$5,461100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,461 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$59,123
Medicare patients
153
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$88,736
FarxigaDapagliflozin Propanediol53$69,224
JanuviaSitagliptin Phosphate30$45,927
EliquisApixaban27$27,436
TradjentaLinagliptin29$25,760
OzempicSemaglutide19$16,979
MounjaroTirzepatide13$14,813
Atorvastatin Calcium725$6,050
Febuxostat33$3,345
SynthroidLevothyroxine Sodium24$2,607
Losartan Potassium337$2,502
Celecoxib80$2,482
Amlodipine Besylate530$2,072
Rosuvastatin Calcium134$1,839
Valsartan62$1,597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$1,523$114,49695 claims
AstraZenecaFarxiga$1,307$69,22453 claims
MerckJanuvia$285$45,92730 claims
PfizerEliquis, Paxlovid$500$28,86539 claims
Novo NordiskOzempic$437$16,97919 claims
Lilly USA, LLCMounjaro$334$14,81313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →